D. Dahms - Nov 30, 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role: Chief Financial Officer
Signature: /s/ Bradford Dahms
Stock symbol: THRX
Transactions as of: Nov 30, 2022
Transactions value $: $10,000
Form type: 4
Date filed: 12/1/2022, 03:35 PM
Previous filing: Feb 23, 2022
Next filing: Feb 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	THRX	Common Stock	Purchase	$10K	+1.5K	+32.37%	$6.66	6.14K	Nov 30, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
F2	Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively.

Content

The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively.